HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Coarse facial features

Also Known As:
Coarce facies; Coarse face; Pugilistic facies
Networked: 31 relevant articles (0 outcomes, 1 trials/studies)

Disease Context: Research Results

Related Diseases

1. Mucopolysaccharidosis II (Hunter Syndrome)
2. Contracture
3. Intellectual Disability (Idiocy)
4. Mucopolysaccharidoses
5. Muscle Hypotonia (Hypotonia)

Experts

1. Chernova, Mairanush: 1 article (05/2022)
2. Gurinova, Elizaveta: 1 article (05/2022)
3. Iwata, Rina: 1 article (05/2022)
4. Loskutova, Kiunniai: 1 article (05/2022)
5. Maksimova, Nadezhda: 1 article (05/2022)
6. Moriwaki, Takahito: 1 article (05/2022)
7. Moriya, Takuya: 1 article (05/2022)
8. Novgorodova, Saina: 1 article (05/2022)
9. Otomo, Takanobu: 1 article (05/2022)
10. Shvedova, Anna: 1 article (05/2022)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Coarse facial features:
1. EnzymesIBA
09/01/2022 - "Affected individuals are deficient in one or more lysosomal enzymes which, depending on the MPS, may cause coarse facial features, short stature, multiple skeletal dysplasia, joint stiffness, or developmental delay. "
05/23/2022 - "Conventional MPS, caused by inborn deficiencies of lysosomal enzymes involved in GAG degradation, display various multisystemic symptoms-including progressive neurological complications, ophthalmological disorders, hearing loss, gastrointestinal and hepatobiliary issues, cardiorespiratory problems, bone and joint abnormalities, dwarfism, and coarse facial features. "
02/01/2020 - "Clinical features differ depending on the specific enzyme deficiency including coarse facial features, cognitive retardation, hepatosplenomegaly, hernias, kyphoscoliosis, corneal clouding, etc. Symptoms of different types are usually similar especially MPS I and II, but may have distinguishable features such as severe neurological problems in MPS III and hydrops fetails in MPS VII. These clinical features contribute to diagnosis, but early and precisely diagnosis in the asymptomatic stage is imperative for better outcomes. "
01/01/2017 - "Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a rare X-linked disorder caused by deficiency of iduronate-2-sulfatase (I2S) enzyme, which leads to the accumulation of partially digested glycosaminoglycans (GAGs) in the lysosomes and induces multisystemic alteration (coarse facial features; skeletal dysplasia; hepatosplenomegaly; joint stiffness and contractures; heart, lung, vision, and hearing disability; profound neurological decline).The purpose of this study is to present the clinical and genetic characteristics of Romanian patients with Hunter syndrome and the genotype-phenotype correlation. "
05/01/2014 - "Coarse facial features and gingival hypertrophy, associated with axial hypotonia, upper airway obstruction, and moderate hepatomegaly, led to the early diagnosis of MPS I at 3 weeks of age and was confirmed by an abnormally elevated amount of dermatan and heparan sulphate in the urine and complete deficiency of alpha-L-iduronidase lysosomal enzyme activity. "
2. GlycosaminoglycansIBA
12/01/2012 - "The accumulation of glycosaminoglycans affects multiple systems, resulting in coarse facial features, short stature, organomegaly, and variable neurological changes from normal intelligence to severe mental retardation and spasticity. "
01/01/2016 - "We report a patient with stage 3 ganglioneuroblastoma who initially presented with clinical and laboratory features consistent with mucopolysaccharidosis including coarse facial features, developmental delay, and an elevated quantitative urine glycosaminoglycan (GAG) level. "
02/01/2015 - "Patients with mucopolysaccharidoses (MPS) have accumulation of glycosaminoglycans in multiple tissues which may cause coarse facial features, mental retardation, recurrent ear and nose infections, inguinal and umbilical hernias, hepatosplenomegaly, and skeletal deformities. "
01/01/2017 - "Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a rare X-linked disorder caused by deficiency of iduronate-2-sulfatase (I2S) enzyme, which leads to the accumulation of partially digested glycosaminoglycans (GAGs) in the lysosomes and induces multisystemic alteration (coarse facial features; skeletal dysplasia; hepatosplenomegaly; joint stiffness and contractures; heart, lung, vision, and hearing disability; profound neurological decline).The purpose of this study is to present the clinical and genetic characteristics of Romanian patients with Hunter syndrome and the genotype-phenotype correlation. "
05/01/1998 - "Coarse facial features, macrodactylia, unilateral corneal dystrophy, generalized osteopenia, progressive neurologic deterioration, and a positive urine spot test for acid mucopolysaccharides suggested mucopolysaccharidosis. "
3. N-Acetylneuraminic Acid (Sialic Acid)IBA
4. Immunoglobulin E (IgE)IBA
5. Insulin (Novolin)FDA Link
6. Iduronidase (alpha-L-Iduronidase)IBA
7. AcidsIBA
8. dimemorfan (AT 17)IBA
9. alpha-Mannosidase (LAMAN)IBA
10. Growth Hormone (Somatotropin)IBA

Therapies and Procedures

1. Therapeutics